Depomed seeks US FDA approval for Serada in hot flashes
This article was originally published in Scrip
Executive Summary
Investors greeted Depomed's news that it finally submitted its US new drug application (NDA) for its experimental menopausal hot flashes drug Serada, an extended-release formulation of gabapentin, by pushing shares of the company up 8.5%, or 47 cents, in after-hours trading on 31 July.